Pepcid Generic Name & Formulations
Famotidine 20mg, 40mg; tabs.
Tabs—30, 100; Susp—50mL; Inj—contact supplier
Active duodenal ulcer. Reduction of the risk duodenal ulcer recurrence in adults. Active gastric ulcer. Symptomatic nonerosive gastroesophageal reflux disease (GERD). Erosive esophagitis (EE). Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas) in adults.
Pepcid Dosage and Administration
Adults and Children
<40kg: use other oral forms. ≥40kg: Duodenal ulcer: 40mg once daily at bedtime or 20mg twice daily for up to 8 weeks. Recurrence: 20mg once daily at bedtime for up to 1 year or as clinically indicated. Gastric ulcer: 40mg once daily at bedtime for up to 8 weeks. GERD: 20mg twice daily for up to 6 weeks. EE: 20mg or 40mg twice daily for up to 12 weeks. Hypersecretory conditions: initially 20mg every 6hrs; individualize; max 160mg every 6hrs. Renal impairment: see full labeling.
History of serious hypersensitivity reactions to H2 receptor antagonists.
Pepcid Boxed Warnings
Symptomatic response does not preclude gastric malignancy; evaluate prior to initiation. Moderate to severe renal impairment (CrCl <50mL/min): reduce to ½ the dose or prolong dosing interval to 36–48hrs. Elderly: use low doses. Pregnancy. Nursing mothers.
Concomitant dasatinib, delavirdine mesylate, cefditoren, fosamprenavir: not recommended. May alter absorption of pH-dependent drugs (eg, atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, rilpivirine). May potentiate CYP1A2 substrates (eg, tizanidine); avoid; if necessary, monitor for hypotension, bradycardia, drowsiness. May give antacids concomitantly.
Pepcid Adverse Reactions
Headache, dizziness, constipation, diarrhea, inj site reactions; rare: CNS reactions, prolonged QT interval in renal impairment (moderate and severe).
Pepcid Clinical Trials
Pepcid Patient Counseling